Investigational Antiretroviral Agents

Faculty:

Joseph J. Eron, Jr., MD Roy M. Gulick, MD, MPH W. David Hardy, MD

Learning Objectives

Upon completion of this activity, participants should be able to:

• Review data on the safety and efficacy of the investigational protease inhibitors (PIs) tipranavir and TMC114 in highly-PI-experienced patients.

• Discuss advances in the development of new reverse transcriptase inhibitors, including NRTIs, NNRTIs, and novel reverse transcriptase inhibitors.

• Discuss recent findings on the following novel classes of antiretrovirals: CCR5 inhibitors, integrase inhibitors, and maturation inhibitors.

Earn CME credit by reading the expert analysis and commentary on Antiretroviral Agents. Topics covered include:

• Novel Reverse Transcriptase Inhibitors
• Advances in Nonnucleoside Reverse Transcriptase Inhibitors
• Further Analysis of Tipranavir/Ritonavir in Highly PI-Experienced Patients
• Use of TMC114/Ritonavir in Highly PI-Experienced Patients
• Other Investigational Protease Inhibitors
• Advances in the Development of CCR5 Inhibitors
• Integrase Inhibitors, Maturation Inhibitors, and Gene Therapy